Note: This document contains side effect information about cabazitaxel. Some of the dosage forms listed on this page may not apply to the brand name Jevtana.
Common side effects of Jevtana include: neutropenia, diarrhea, nausea, and vomiting. Other side effects include: febrile neutropenia, hypotension, and dehydration. See below for a comprehensive list of adverse effects.
Applies to cabazitaxel: intravenous solution
Intravenous route (Solution)
NeutropeniaNeutropenic deaths have been reported. Monitor for neutropenia with frequent blood cell counts. Cabazitaxel is contraindicated in patients with neutrophil counts of less than or equal to 1500 cells/mm(3). Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.Severe HypersensitivitySevere hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the cabazitaxel infusion and administration of appropriate therapy. Patients should receive premedication. Cabazitaxel is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to drugs formulated with polysorbate 80.
Along with its needed effects, cabazitaxel (the active ingredient contained in Jevtana) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking cabazitaxel:
Incidence not known
Some side effects of cabazitaxel may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to cabazitaxel: intravenous solution
The most common adverse events were anemia, leukopenia, neutropenia, thrombocytopenia, and diarrhea.
Very common (10% or more): Anemia (98%), leukopenia (96%), neutropenia (94%), thrombocytopenia (48%)
Common (1% to 10%): Febrile neutropenia
Very common (10% or more): Diarrhea (47%), nausea (34%), vomiting (22%), constipation (20%), abdominal pain (17%), dyspepsia (10%)
Common (1% to 10%): Abdominal pain upper, hemorrhoids, gastroesophageal reflux disease, rectal hemorrhage, dry mouth, abdominal distension
Frequency not reported: Death related to diarrhea and electrolyte imbalance, GI hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, colitis
Postmarketing reports: Gastritis, intestinal obstruction
Very common (10% or more): Fatigue (37%), dysgeusia (11%)
Common (1% to 10%): Dizziness, peripheral neuropathy, headache, peripheral sensory neuropathy, paresthesia, lethargy, hypoesthesia, tinnitus, vertigo, sciatica
Frequency not reported: Peripheral motor neuropathy, fatal cerebral hemorrhage
Very common (10% or more): Asthenia (20%), pyrexia (12%)
Common (1% to 10%): Mucosal inflammation, pain, death due to causes other than disease progression, malaise
Very common (10% or more): Dyspnea (12%), cough (11%)
Common (1% to 10%): Oropharyngeal pain
Common (1% to 10%): Peripheral edema, arrhythmia, hypotension, deep vein thrombosis, hypertension, tachycardia, grade 3 or higher arrhythmias, orthostatic hypotension, hot flush, flushing, atrial fibrillation
Uncommon (0.1% to 1%): Cardiac failure, cardiac arrest, fatal ventricular fibrillation
Uncommon (0.1% to 1%): Grade 3 to 4 increased AST, grade 3 to 4 increased ALT, increased bilirubin
Frequency not reported: Fatal renal failure
Very common (10% or more): Anorexia (16%)
Common (1% to 10%): Weight decreased, dehydration, edema, hyperglycemia, hypokalemia
Very common (10% or more): Hematuria (17%)
Common (1% to 10%): Dysuria, pollakiuria, urinary retention, urinary incontinence, ureteric obstruction, pelvic pain
Common (1% to 10%): AST increased, transaminases increased
Uncommon (0.1% to 1%): ALT increased, bilirubin increased
Common (1% to 10%): Hypersensitivity
Very common (10% or more): Back pain (16%), arthralgia (10.5%)
Common (1% to 10%): Pain in extremity, muscle spasms, myalgia, musculoskeletal chest pain, flank pain, chills
Common (1% to 10%): Urinary tract infection, influenza, cystitis, upper respiratory tract infection, pneumonia, cellulitis, herpes zoster, septic shock, sepsis, candidiasis
Uncommon (0.1% to 1%): Neutropenic sepsis, neutropenic infections
Frequency not reported: Fatal infection
Very common (10% or more): Alopecia (10%)
Common (1% to 10%): Dry skin, erythema
Common (1% to 10%): Conjunctivitis, increased lacrimation
Common (1% to 10%): Anxiety, confusional state
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Jevtana